1. Home
  2. ABVX vs BCPC Comparison

ABVX vs BCPC Comparison

Compare ABVX & BCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABVX
  • BCPC
  • Stock Information
  • Founded
  • ABVX 2013
  • BCPC 1967
  • Country
  • ABVX France
  • BCPC United States
  • Employees
  • ABVX N/A
  • BCPC N/A
  • Industry
  • ABVX
  • BCPC Major Chemicals
  • Sector
  • ABVX
  • BCPC Industrials
  • Exchange
  • ABVX Nasdaq
  • BCPC Nasdaq
  • Market Cap
  • ABVX 5.3B
  • BCPC 5.3B
  • IPO Year
  • ABVX N/A
  • BCPC N/A
  • Fundamental
  • Price
  • ABVX $84.01
  • BCPC $156.34
  • Analyst Decision
  • ABVX Strong Buy
  • BCPC Strong Buy
  • Analyst Count
  • ABVX 8
  • BCPC 1
  • Target Price
  • ABVX $90.63
  • BCPC $189.00
  • AVG Volume (30 Days)
  • ABVX 1.2M
  • BCPC 136.7K
  • Earning Date
  • ABVX 08-11-2025
  • BCPC 10-24-2025
  • Dividend Yield
  • ABVX N/A
  • BCPC 0.56%
  • EPS Growth
  • ABVX N/A
  • BCPC 21.42
  • EPS
  • ABVX N/A
  • BCPC 4.36
  • Revenue
  • ABVX $7,073,400.00
  • BCPC $985,930,000.00
  • Revenue This Year
  • ABVX $25.23
  • BCPC $9.58
  • Revenue Next Year
  • ABVX N/A
  • BCPC $6.32
  • P/E Ratio
  • ABVX N/A
  • BCPC $35.93
  • Revenue Growth
  • ABVX N/A
  • BCPC 5.74
  • 52 Week Low
  • ABVX $4.77
  • BCPC $145.70
  • 52 Week High
  • ABVX $92.91
  • BCPC $185.96
  • Technical
  • Relative Strength Index (RSI)
  • ABVX 67.94
  • BCPC 42.34
  • Support Level
  • ABVX $82.72
  • BCPC $154.72
  • Resistance Level
  • ABVX $91.30
  • BCPC $159.61
  • Average True Range (ATR)
  • ABVX 3.62
  • BCPC 2.69
  • MACD
  • ABVX -1.13
  • BCPC -0.73
  • Stochastic Oscillator
  • ABVX 47.89
  • BCPC 15.58

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

About BCPC Balchem Corporation

Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.

Share on Social Networks: